Luckett, Patrick H. http://orcid.org/0000-0003-2262-6605
Olufawo, Michael
Lamichhane, Bidhan
Park, Ki Yun
Dierker, Donna
Verastegui, Gabriel Trevino
Yang, Peter
Kim, Albert H.
Chheda, Milan G.
Snyder, Abraham Z.
Shimony, Joshua S.
Leuthardt, Eric C.
Funding for this research was provided by:
Washington University Yearlong Research Program Dean’s Fellowship
National Cancer Institute (R01CA203861, R01CA203861, R01CA203861)
National Institute of Neurological Disorders and Stroke (U24NS109103, U24NS109103, U24NS109103)
National Institute of Biomedical Imaging and Bioengineering (R01EB026439, R01EB026439, P41EB018783)
Article History
Received: 3 August 2023
Accepted: 26 August 2023
First Online: 5 September 2023
Declarations
:
: Patrick Luckett, Joshua Shimony, Eric Leuthardt, Ki Yun Park, Abraham Snyder, and/or Washington University in St. Louis may receive royalty income based on a technology developed by Patrick Luckett, Joshua Shimony, Eric Leuthardt, Abraham Snyder, and Ki Yun Park and licensed by Washington University to Sora Neuroscience. Eric Leuthardt owns stock in Neurolutions, General Sensing, Face to Face Biometrics, Caeli Vascular, Acera, Sora Neuroscience, Inner Cosmos, Kinetrix, NeuroDev, Inflexion Vascular, and Petal Surgical. Washington University has equity ownership of Neurolutions. The remaining authors declare no financial interest.
: This study was approved by the Washington University in St. Louis Institutional Review Board, and informed consent was obtained from all participants in this study. This manuscript contains no individual person’s data in any form.